Page not found – ARNA Genomics US Inc. https://arna.bio Breakthrough cancer detection technologies Fri, 12 Mar 2021 09:29:51 +0000 en-US hourly 1 https://wordpress.org/?v=6.2.1 https://arna.bio/wp-content/uploads/2018/05/apple-touch-icon-50x50.png Page not found – ARNA Genomics US Inc. https://arna.bio 32 32 CEO Global Award goes to ARNA Genomics founder Egor Melnikov https://arna.bio/ceo-global-award-2021-en/ https://arna.bio/ceo-global-award-2021-en/#respond Fri, 05 Mar 2021 09:23:00 +0000 https://arna.bio/?p=1590 […]]]> Egor Melnikov, Founder of ARNA Genomics US Inc., was honored by CEO Today Magazine with a 2021 CEO Global award for scientific research and business results achieved over the last 12 months. The magazine recognizes those CEOs who have disrupted the industry’s status quo and taken their company to new heights of innovation and growth across the globe.

«I am grateful for the high appreciation. It all became possible due to our team exceptional competency, business speed accomplishment and strong investors belief. As soon as we revealed the results of proof-of-concept study investor’s were convinced in the company’s potential. They invested $3.5 million in round A. The money raised was immediately used for further research and obtaining a patent and unprecedented for BC detections results. We had undertaken a series of extensive blinded studies on 1,160 patients in Russia and are preparing to launch clinical trials this spring in New Jersey and Manheim. We intend to finalize CE-Mark registration in Europe and LDT status from the FDA in the U.S.» — Egor says.

The full text of an interview: https://globalawards.ceotodaymagazine.com/winners-edition/122/

Next year I see as even filled with discoveries and public announcements. We are preparing a number of patents with special attention to ARNA-3 technology applicability for various diseases other than cancer. We are sure that as soon as published they will attract attention of the professional community and earn international recognition. Our vision is that we will need about 2 or 3 more investment rounds before we can be called as “Unicorn” with a valuation above $1 billion: $20 million in 2 years and another $85 million in 4. We do trust in what we do and “ARNA – way”

]]>
https://arna.bio/ceo-global-award-2021-en/feed/ 0
ARNA received the 2020 National Technological Initiative Award. https://arna.bio/arna-received-the-2020-national-technological-initiative-award/ https://arna.bio/arna-received-the-2020-national-technological-initiative-award/#respond Fri, 25 Dec 2020 20:00:00 +0000 https://arna.bio/?p=1573 […]]]> According to the results of 2020, the work of ARNA Genomics was noted with gratitude by the Special Representative of the President of the Russian Federation Dmitry Peskov for digital and technological development in the framework of the National Technological Initiative 20.35 “For achieving outstanding results in the implementation of the National Technological Initiative”.

Video of the award ceremony (Russian only):

]]>
https://arna.bio/arna-received-the-2020-national-technological-initiative-award/feed/ 0
«We consider it important to look for super correct, super-accurate expertise» – Egor Melnikov shared his personal ARNA journey story in an exclusive interview with AsiaTechDaily https://arna.bio/asiatechdaily-en/ https://arna.bio/asiatechdaily-en/#respond Thu, 10 Dec 2020 12:00:00 +0000 https://arna.bio/?p=1557 […]]]>

«Back in 2013, a friend of mine asked me what my actual motivation was. The answer came easily: “I want to create a company based on my father Anatoly Melnikov’s developments for early cancer detection based on DNA methylation.” And it’s not just an ambition. It’s a passion to help the lives of others.

Exactly 7 years ago, we created LLC BIOMARKER-RU together. In 2018, ARNA Genomics US was registered. My best childhood friend George Nikitin is now a Co-founder and a Chief Operating Officer of the company».

Read the full story on AsiaTechDaily

]]>
https://arna.bio/asiatechdaily-en/feed/ 0
ARNA Genomics raises $3,5 million in series A funding on ARNA Breast cancer test systems https://arna.bio/arna-series-a-en/ https://arna.bio/arna-series-a-en/#respond Thu, 17 Sep 2020 14:42:46 +0000 https://arna.bio/?p=1530 […]]]> /USA, Wilmington, September 17, 2020/ – ARNA Genomics US Inc, which develops tests for early stage cancer by detecting specific fragments of nucleic acids in plasma, announced today closing of the $3,5 million series A with a leading investor – Xploration Capital venture fund. Raised funding will be used for clinical validation of ARNA Breast – a first unique test for breast cancer.   Jointly with Sechenov University the Company has conducted a proof-of-concept study of “ARNA Breast” which showed accuracy over 90%. This outstanding result far exceeds parameters of breast cancer tests developed by such companies as GRAIL (investment about $2 billion) and Thrive Earlier Detection (investment about $350 million). “ARNA Breast” is a first test in the product line with which ARNA Genomics begins its expansion to the global market. Tests for stomach, pancreatic and ovarian cancer are currently under development and expected in the nearest future.  

Prof. Charles R. Cantor, molecular geneticist, member of the US National Academy of Sciences:

ARNA Genomics has a unique approach to develop and deploy liquid biopsy tests for detecting cancers and monitoring their response to therapy. Because liquid biopsies are noninvasive (typically just a blood draw, a urine sample or a swab) and inexpensive, they are likely to become broadly used diagnostic tests. This field is extremely competitive, but because ARNA [Genomics US Inc.] does things differently it is likely to acquire strong intellectual property and a significant market share.

Series A funds will be used for further clinical trials in the United States, Europe and CIS. The Company also plans to expand operations to Indian and Chinese markets.   “ARNA Breast” test consists of two parts or protocols. One involves highly precise measurement of circulating free DNA fragments left in blood plasma, the other – analysis of enzymatic activity.  Protocols and “know-hows” are currently being patented.  

Egor Melnikov, founder and CEO of ARNA Genomics:

We greatly appreciate investors’ belief in our project. Negotiations took quite a long time. Pre-seed, seed, pre-A series were much easier than series A. During the period of proof-of-concept study followed by thorough due diligence we have managed to bring together a team of exceptional and talented people, which is a second crucial point for any startup after having a great technology. Raised funding will allow us to conduct a number of strong evidential studies, which will let us to make our tests available to the patients in the nearest future.

]]>
https://arna.bio/arna-series-a-en/feed/ 0
“This is our dream!” https://arna.bio/this-is-our-dream-en/ https://arna.bio/this-is-our-dream-en/#respond Thu, 09 Jan 2020 12:00:00 +0000 https://arna.bio/?p=1503 […]]]> “This is our dream!” With these words ended the report of the Director of the Institute of Cluster Oncology of Sechenov University, Professor M.I. Sekacheva with the results of proof-of-concept research, presented in the framework of the session “Innovation in Oncology” with the support of the “Skolkovo” Foundation at the XXIII Russian Oncology Congress on November 12, 2019.

Professor Sekacheva M.I. in her speech presented design and progress of the study, stressed the impressive results and the main advantages of ARNA technology.

Video version of the report was published on the official Internet portal of the Russian Society of Clinical Oncology https://rosoncoweb.ru. The full version of Professor M.I. Sekacheva’s speech is available here (Audio – Russian, English subtitles pending:

]]>
https://arna.bio/this-is-our-dream-en/feed/ 0
Test for early breast cancer detection “ARNA Breast” showed impressive results of clinical efficacy according to proof-of-concept study https://arna.bio/sechenov-results-2019-en/ https://arna.bio/sechenov-results-2019-en/#respond Tue, 24 Sep 2019 12:00:51 +0000 https://arna.bio/?p=1467 […]]]> September 24, 2019, Moscow, Russia

ARNA Genomics US Inc., an innovative biotechnology company specializing in the development and implementation of diagnostic methods for early cancer detection, announced the successful completion of a proof-of-concept study with valid evidence results of the test in vitro diagnostic for early breast cancer detection “ARNA Breast”.

An open observational clinical and laboratory study of the proof-of-concept “Analysis of the effectiveness of ARNA Breast method for the diagnosis of breast cancer” was conducted at the Research Center for Personalized Oncology Research Institute of Personalized Medicine of I.M. Sechenov First Moscow State Medical University (Sechenov University).

The study analyzed plasma samples taken from women aged 18 to 75 years old with a newly diagnosed and histologically confirmed diagnosis of breast cancer of all biological subtypes before the appointment of any type of therapy and in healthy volunteers. The final analysis included 80 biosamples. According to two laboratory analysis protocols, the following statistically significant results were obtained: sensitivity (SE) = 100.0% (79-100% CI 0.99), specificity (SP)=85% (59-97% CI 0.99), negative predictive value (NPV) = 100.0% (79-100% CI 0.99), positive predictive value (PPV) = 85% (59-97% CI 0.99).

CEO and Founder of ARNA Genomics US Inc. Egor Melnikov said: “We are encouraged by the data that we have been moving to for more than 5 years, and we believe that the result can be a bright and attractive signal for Russian and foreign investors not only from the field of “technologies for women”(Femtech), but also from biomedicine and biopharmaceuticals in connection with own scientific platform in the field of “liquid biopsy” – ARNA, which allows to create tests for the early detection of various types of cancer based on blood plasma analysis.”

According to the company, the implementation of ARNA Breast test in clinical practice can be of great practical importance for Russian health care, in particular, when conducting routine physical examinations and annual prophylactic medical examination (screening) of the population, especially at-risk groups – women older than 50 years and not having nodal formations in breast tissue or previously not detected by traditional instrumental methods.

About company:

ARNA Genomics US Inc. – Biotechnology company focused on the development of liquid biopsy technologies. Based on the basis of a research laboratory, it is engaged in the development and research of methods for the early cancer diagnosis and the introduction of diagnostic tests on the markets for early cancer detection. The company sees its mission in extending and improving the quality of life of people through the widespread adoption worldwide of the latest screening methods, early diagnosis and monitoring of the treatment of cancer, which have no analogues in the effectiveness of screening.

About Product:

ARNA Breast is an in vitro diagnostic test based on a combined analysis of the content of oncogenes fragments in cell-free DNA and plasma enzyme activity for the early breast cancer detection in women.

]]>
https://arna.bio/sechenov-results-2019-en/feed/ 0